• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转诊至一家学术医疗中心的老年人中野生型和V122I转甲状腺素蛋白所致心脏淀粉样变性的比较。

Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center.

作者信息

Givens Raymond C, Russo Chris, Green Philip, Maurer Mathew S

机构信息

Clinical Cardiovascular Research Laboratory for the Elderly, Center for Advanced Cardiac Care, Division of Cardiology, Columbia College of Physicians & Surgeons, 622 West 168th Street, PH 12-1291, NY, USA.

出版信息

Aging health. 2013 Apr 1;9(2):229-235. doi: 10.2217/ahe.13.10.

DOI:10.2217/ahe.13.10
PMID:24073013
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3780445/
Abstract

AIMS

In the USA, transthyretin cardiac amyloidosis usually results from 'wild-type' transthyretin (senile cardiac amyloidosis [SCA]) or the V122I variant.

PATIENTS & METHODS: We compared presentations and outcomes among SCA and V122I patients referred to the Center for Advanced Cardiac Care at Columbia University Medical Center (NY, USA) between 2001 and 2012.

RESULTS

V122I patients were younger (mean: 71 years, standard deviation [SD]: 7) than SCA patients (mean: 77, SD: 6; p = 0.0002) and 96% were black compared with 3% of SCA patients (p < 0.0001). Average ejection fraction was lower among V122I patients (mean: 25% [SD: 12] vs mean: 47% [SD: 15]; p = 0.0001), as was mean cardiac index. Median time to death or orthotopic heart transplant was 36.4 months for V122I patients and 66.5 for SCA patients (p = 0.09).

CONCLUSION

In this study of patients with transthyretin cardiac amyloidosis, V122I patients presented to a tertiary academic medical center at a younger age than SCA patients but had higher levels of cardiac dysfunction, despite genetic screening availability. There was a trend toward shorter time to orthotopic heart transplant or death among V122I patients. Whether this is a result of a different biologic progression or late diagnosis requires further study.

摘要

目的

在美国,转甲状腺素蛋白心脏淀粉样变性通常由“野生型”转甲状腺素蛋白(老年心脏淀粉样变性[SCA])或V122I变体引起。

患者与方法

我们比较了2001年至2012年间转诊至美国纽约哥伦比亚大学医学中心高级心脏护理中心的SCA患者和V122I患者的临床表现和预后。

结果

V122I患者比SCA患者年轻(平均年龄:71岁,标准差[SD]:7)(平均年龄:77岁,SD:6;p = 0.0002),96%为黑人,而SCA患者为3%(p < 0.0001)。V122I患者的平均射血分数较低(平均:25%[SD:12] vs平均:47%[SD:15];p = 0.0001),平均心脏指数也是如此。V122I患者至死亡或原位心脏移植的中位时间为36.4个月,SCA患者为66.5个月(p = 0.09)。

结论

在这项转甲状腺素蛋白心脏淀粉样变性患者的研究中, V122I患者比SCA患者更年轻就就诊于三级学术医疗中心,但尽管有基因筛查,其心脏功能障碍水平更高。V122I患者接受原位心脏移植或死亡的时间有缩短趋势。这是不同生物学进展还是晚期诊断的结果需要进一步研究。

相似文献

1
Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center.转诊至一家学术医疗中心的老年人中野生型和V122I转甲状腺素蛋白所致心脏淀粉样变性的比较。
Aging health. 2013 Apr 1;9(2):229-235. doi: 10.2217/ahe.13.10.
2
Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.使用血清视黄醇结合蛋白 4 和临床预测模型鉴定转甲状腺素蛋白心脏淀粉样变性。
JAMA Cardiol. 2017 Mar 1;2(3):305-313. doi: 10.1001/jamacardio.2016.5864.
3
Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS).转甲状腺素蛋白(ATTR)心脏淀粉样变性继发于 V122I 突变和野生型转甲状腺素蛋白的患者的压力-容积关系:转甲状腺素蛋白心脏淀粉样变性研究(TRACS)。
Circ Heart Fail. 2011 Mar;4(2):121-8. doi: 10.1161/CIRCHEARTFAILURE.109.910455. Epub 2010 Dec 29.
4
Comparison of cardiac involvement, extracardiac manifestations and outcomes between homozygote and heterozygote transthyretin p.Val142Ile (V122I) variant in patients with hereditary transthyretin amyloidosis: a cohort study.家族性转甲状腺素蛋白淀粉样变性患者纯合子和杂合子 transthyretin p.Val142Ile (V122I) 变异的心脏受累、心脏外表现和结局比较:一项队列研究。
Amyloid. 2023 Dec;30(4):407-415. doi: 10.1080/13506129.2023.2227322. Epub 2023 Jun 28.
5
Association of the V122I Transthyretin Amyloidosis Genetic Variant With Cardiac Structure and Function in Middle-aged Black Adults: Coronary Artery Risk Development in Young Adults (CARDIA) Study.V122I转甲状腺素蛋白淀粉样变性基因变异与中年黑人成年人心脏结构和功能的关联:青年成人冠状动脉风险发展(CARDIA)研究
JAMA Cardiol. 2021 Jun 1;6(6):718-722. doi: 10.1001/jamacardio.2020.6623.
6
Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).前瞻性评估野生型和 V122I 突变转甲状腺素蛋白淀粉样心肌病的发病率和死亡率:转甲状腺素蛋白淀粉样变性心肌病研究(TRACS)。
Am Heart J. 2012 Aug;164(2):222-228.e1. doi: 10.1016/j.ahj.2012.04.015.
7
Low Prevalence of Clinically Apparent Cardiac Amyloidosis Among Carriers of Transthyretin V122I Variant in a Large Electronic Medical Record.在大型电子病历中,转甲状腺素蛋白 V122I 变异体携带者中临床明显心脏淀粉样变性的患病率较低。
Am J Med. 2021 Feb;134(2):e98-e100. doi: 10.1016/j.amjmed.2020.06.031. Epub 2020 Aug 28.
8
The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients.与变异转甲状腺素蛋白 122 位异亮氨酸型非洲裔加勒比地区患者相关的心脏淀粉样变的心电图特征。
Am Heart J. 2012 Jul;164(1):72-9. doi: 10.1016/j.ahj.2012.04.013.
9
Clinical Implications of the Amyloidogenic V122I Transthyretin Variant in the General Population.人群中淀粉样变 V122I 转甲状腺素变体的临床意义。
J Card Fail. 2022 Mar;28(3):403-414. doi: 10.1016/j.cardfail.2021.09.015. Epub 2021 Oct 9.
10
Cardiovascular Disease and Mortality in Black Women Carrying the Amyloidogenic V122I Transthyretin Gene Variant.携带有淀粉样变 V122I 转甲状腺素蛋白基因变异的黑人女性中的心血管疾病和死亡率。
JACC Heart Fail. 2023 Sep;11(9):1189-1199. doi: 10.1016/j.jchf.2023.02.003. Epub 2023 Mar 5.

引用本文的文献

1
Vutrisiran in Transthyretin Amyloidosis: A Pooled Safety Analysis of HELIOS-A and HELIOS-B.伏硫西汀治疗转甲状腺素蛋白淀粉样变性:HELIOS - A和HELIOS - B的汇总安全性分析
JACC Adv. 2025 Aug 22;4(9):102066. doi: 10.1016/j.jacadv.2025.102066.
2
The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement.野生型转甲状腺素蛋白介导(ATTRwt)淀粉样变性的诊断之旅:多系统受累的途径。
Orphanet J Rare Dis. 2024 Nov 8;19(1):419. doi: 10.1186/s13023-024-03407-3.
3
Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.他法米替尼的安全性评估:FDA 不良事件报告系统(FAERS)事件的真实世界药物警戒研究。
BMC Pharmacol Toxicol. 2024 Sep 27;25(1):71. doi: 10.1186/s40360-024-00790-2.
4
Challenges associated with managing treatment complications in an older patient with cardiac amyloidosis.老年心脏淀粉样变性患者治疗并发症管理相关的挑战。
Egypt Heart J. 2024 Jun 18;76(1):75. doi: 10.1186/s43044-024-00507-0.
5
Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review.六分钟步行试验作为心肌病临床试验的临床终点,包括ATTR-CM:系统文献回顾。
J Comp Eff Res. 2024 Jul;13(7):e230158. doi: 10.57264/cer-2023-0158. Epub 2024 Jun 13.
6
Prevalence of transthyretin amyloid cardiomyopathy in pacemaker patients.起搏器患者转甲状腺素蛋白淀粉样心肌病的患病率。
ESC Heart Fail. 2024 Apr;11(2):871-876. doi: 10.1002/ehf2.14645. Epub 2024 Jan 10.
7
Fat biopsy from a pocket of cardiac implantable electronic device: An alternative diagnostic option for cardiac amyloidosis.心脏植入式电子设备囊袋脂肪活检:心脏淀粉样变性的一种替代诊断方法。
HeartRhythm Case Rep. 2022 May 18;8(8):554-557. doi: 10.1016/j.hrcr.2022.05.008. eCollection 2022 Aug.
8
Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis.转甲状腺素蛋白心脏淀粉样变的超声心动图参数进展与预后。
Eur J Heart Fail. 2022 Sep;24(9):1700-1712. doi: 10.1002/ejhf.2606. Epub 2022 Jul 27.
9
Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges.转甲状腺素蛋白淀粉样心肌病的治疗:当前选择、未来展望与挑战
J Clin Med. 2022 Apr 12;11(8):2148. doi: 10.3390/jcm11082148.
10
Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis.淀粉样蛋白成核作为转甲状腺素蛋白心脏淀粉样变性的疾病机制和治疗靶点。
Heart Fail Rev. 2022 Nov;27(6):2187-2200. doi: 10.1007/s10741-022-10237-7. Epub 2022 Apr 6.

本文引用的文献

1
Transthyretin (TTR) cardiac amyloidosis.转甲状腺素蛋白(TTR)心脏淀粉样变性
Circulation. 2012 Sep 4;126(10):1286-300. doi: 10.1161/CIRCULATIONAHA.111.078915.
2
Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).前瞻性评估野生型和 V122I 突变转甲状腺素蛋白淀粉样心肌病的发病率和死亡率:转甲状腺素蛋白淀粉样变性心肌病研究(TRACS)。
Am Heart J. 2012 Aug;164(2):222-228.e1. doi: 10.1016/j.ahj.2012.04.015.
3
The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients.与变异转甲状腺素蛋白 122 位异亮氨酸型非洲裔加勒比地区患者相关的心脏淀粉样变的心电图特征。
Am Heart J. 2012 Jul;164(1):72-9. doi: 10.1016/j.ahj.2012.04.013.
4
Diflunisal for ATTR cardiac amyloidosis.双氟尼酸用于治疗转甲状腺素蛋白淀粉样变性心肌病。
Congest Heart Fail. 2012 Nov-Dec;18(6):315-9. doi: 10.1111/j.1751-7133.2012.00303.x. Epub 2012 Jul 2.
5
Tafamidis for transthyretin amyloidosis.塔非酰胺用于转甲状腺素蛋白淀粉样变性。
Drugs Today (Barc). 2012 May;48(5):331-7. doi: 10.1358/dot.2012.48.5.1808486.
6
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.塔法米迪,一种强效和选择性的转甲状腺素蛋白动力学稳定剂,可抑制淀粉样蛋白级联反应。
Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9629-34. doi: 10.1073/pnas.1121005109. Epub 2012 May 29.
7
Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy.用于治疗转甲状腺素蛋白相关性多发性神经病的反义疗法的临床开发。
Amyloid. 2012 Jun;19 Suppl 1:43-4. doi: 10.3109/13506129.2012.673140. Epub 2012 Apr 12.
8
Transthyretin cardiac amyloidoses in older North Americans.北美老年人中的转甲状腺素蛋白心脏淀粉样变性。
J Am Geriatr Soc. 2012 Apr;60(4):765-74. doi: 10.1111/j.1532-5415.2011.03868.x. Epub 2012 Feb 13.
9
Relation of clinical, echocardiographic and electrocardiographic features of cardiac amyloidosis to the presence of the transthyretin V122I allele in older African-American men.老年非裔美国男性心脏淀粉样变的临床、超声心动图和心电图特征与转甲状腺素蛋白 V122I 等位基因的关系。
Am J Cardiol. 2011 Aug 1;108(3):440-4. doi: 10.1016/j.amjcard.2011.03.069. Epub 2011 May 19.
10
Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies.载脂蛋白淀粉样变转甲状腺素 Val122Ile 等位基因在动脉粥样硬化风险社区(ARIC)和心血管健康(CHS)研究中的非洲裔美国人中的意义。
Am Heart J. 2010 May;159(5):864-70. doi: 10.1016/j.ahj.2010.02.006.